









Markets
/
Stocks
/
nasdaq-idya
/

IDEAYA Biosciences Inc

IDYA

32.170USD

+0.400+1.26%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

2.82BMarket Cap

LossP/E TTM



IDEAYA Biosciences Inc

32.170

+0.400+1.26%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of IDEAYA Biosciences Inc

Currency: USD Updated: 2026-02-06

Key Insights

IDEAYA Biosciences Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 12 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 49.94.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

IDEAYA Biosciences Inc's Score

Industry at a Glance

Industry Ranking

12 / 392

Overall Ranking

93 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

IDEAYA Biosciences Inc Highlights

StrengthsRisks

IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).

Growing

The company is in a growing phase, with the latest annual income totaling USD 7.00M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 7.00M.

Fairly Valued

The company’s latest PE is -16.96, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 96.76M shares, decreasing 14.85% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 4.62K shares of this stock.

Analyst Rating

Based on 19 analysts

Buy

Current Rating

49.941

Target Price

+57.20%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of IDEAYA Biosciences Inc is 9.21, ranking 11 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

9.21

Change



Financials

9.66

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.60

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.78

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

IDEAYA Biosciences Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of IDEAYA Biosciences Inc is 6.47, ranking 272 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -16.96, which is -76.57% below the recent high of -3.97 and -41.54% above the recent low of -24.00.

Score

Industry at a Glance

Previous score

6.47

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 12/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of IDEAYA Biosciences Inc is 8.53, ranking 102 out of 392 in the Biotechnology & Medical Research industry. The average price target is 46.00, with a high of 79.00 and a low of 31.00.

Score

Industry at a Glance

Previous score

8.53

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 19 analysts

Buy

Current Rating

49.941

Target Price

+57.20%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

IDEAYA Biosciences Inc

IDYA

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of IDEAYA Biosciences Inc is 6.66, ranking 199 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 36.29 and the support level at 29.80, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.56

Change

0.1

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.728

Sell

RSI(14)

40.042

Neutral

STOCH(KDJ)(9,3,3)

19.260

Neutral

ATR(14)

1.454

Low Volatility

CCI(14)

-111.286

Sell

Williams %R

87.803

Oversold

TRIX(12,20)

-0.270

Sell

StochRSI(14)

22.679

Sell

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

33.102

Sell

MA10

33.355

Sell

MA20

34.728

Sell

MA50

34.784

Sell

MA100

32.000

Buy

MA200

27.042

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of IDEAYA Biosciences Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 110.37%, representing a quarter-over-quarter decrease of 8.50%. The largest institutional shareholder is The Vanguard, holding a total of 5.00M shares, representing 5.70% of shares outstanding, with 1.64% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

13.15M

+0.07%

Capital Research Global Investors

6.55M

Janus Henderson Investors

6.43M

+3.58%

BlackRock Institutional Trust Company, N.A.

6.34M

-5.05%

The Vanguard Group, Inc.

Star Investors

4.90M

-0.40%

Federated Hermes Global Investment Management Corp.

4.63M

-0.03%

Point72 Asset Management, L.P.

Star Investors

3.82M

-24.12%

Baker Bros. Advisors LP

3.28M

+54.59%

State Street Investment Management (US)

3.24M

-4.28%

Adage Capital Management, L.P.

2.90M

+134.24%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of IDEAYA Biosciences Inc is 6.75, ranking 21 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.09. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.